Simona Protrka

Dr. Simona Protrka


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MZMilan Zaric
Milan Zaric
PCPetar Predrag Canovic
Petar Predrag Canovic
RZRadica Zivkovic Zaric
Radica Zivkovic Zaric
SPSimona Protrka
Simona Protrka
MGMiona Glisic
Miona Glisic
Cancer therapy is rapidly evolving from a one-size-fits-all paradigm toward highly personalized approaches. Traditional chemotherapies and radiotherapies, while broadly applied, often yield suboptimal outcomes due to tumor heterogeneity and are limited by significant toxicities. In contrast, precision oncology tailors prevention, diagnosis, and treatment to the individual patient’s genetic and molecular profile. Key advancements underscore this shift: molecularly targeted drugs (e.g., trastuzumab for HER2-positive breast cancer, EGFR and ALK inhibitors for lung cancer) have improved efficacy and reduced toxicity compared to conventional therapy. Pharmacokinetic (PK) and pharmacodynamic (PD) considerations are central to personalizing treatment, explaining variability in drug exposure and response among patients and guiding dose optimization. Modern strategies like therapeutic drug monitoring and model-informed precision dosing seek to maintain drug levels in the therapeutic range, improving outcomes. Immunotherapies, including checkpoint inhibitors and CAR-T cells, have transformed oncology, though patient selection via biomarkers (such as PD-L1 expression or tumor mutational burden) is critical to identify likely responders. Innovative drug delivery systems, notably nanomedicine, address PK challenges by enhancing tumor-specific drug accumulation and enabling novel therapeutics. Furthermore, rational combination regimens (informed by PK/PD and tumor biology) are being designed to achieve synergistic efficacy and overcome resistance. Key barriers include the high cost of biomarker testing, insufficient laboratory infrastructure, and inconsistent reimbursement policies. Operational inefficiencies such as long turnaround times or lack of clinician awareness further limit the use of precision diagnostics. Regulatory processes also remain complex, particularly around the co-development of targeted drugs and companion diagnostics, and the evidentiary requirements for rare subgroups. Addressing these barriers will require harmonized policies, investment in infrastructure, and educational initiatives to ensure that the promise of personalized medicine becomes accessible to all patients. Ensuring that advances are implemented responsibly—guided by pharmacological insights, supported by real-world evidence, and evaluated within ethical and economic frameworks—will be critical to realizing the full potential of personalized cancer medicine.

11 July 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
DPDragica Pavlovic
Dragica Pavlovic
MJMarina Gazdic Jankovic
Marina Gazdic Jankovic
DPDragana Papic
Dragana Papic
Nikolina KastratovicNikolina Kastratovic
Nikolina Kastratovic
Nikola JovicNikola Jovic
Nikola Jovic
BLBiljana Ljujic
Biljana Ljujic
Non-celiac gluten sensitivity (NCGS), even though it is a term defined for more than four decades, is still an enigmatic clinical entity. This is primarily due to the absence of specific diagnostic criteria, with most reports relying on patients’ self-diagnosis. Individuals with NCGS experience intestinal (abdominal pain, bloating, diarrhea, or constipation) and extraintestinal symptoms (“foggy mind,” depression, anxiety, and deterioration of psychiatric conditions) after gluten consumption. Frequent disregard and oversight of extraintestinal manifestations, such as psychiatric symptoms, further complicates NCGS. The lack of understanding about NCGS causes individuals living with this condition to experience distress, frustration, and stigmatization. An impaired intestinal barrier, gut dysbiosis, and alterations in the gut–brain axis are proposed as key factors in the NCGS and psychiatric symptoms associated with NCGS. None of these links are yet definitive, and the methodological limitations of existing studies—small samples, self-reported diagnoses, and insufficient blinding—demand that conclusions be drawn with appropriate restraint. The purpose of this review is to provide an up-to-date understanding of the pathophysiology of NCGS and psychiatric symptoms associated with NCGS. Future studies should focus on development of reliable, objective diagnostic markers for NCGS and on the design of adequately powered, double-blind, placebo-controlled trials that incorporate validated psychiatric outcome measures alongside intestinal indices.

Verified
Journal Article
Open access
RZRadica Zivkovic Zaric
Radica Zivkovic Zaric
MZMilan Zaric
Milan Zaric
SPSimona Protrka
Simona Protrka
VAVeljko Andrić
Veljko Andrić
NANeda Slobodan Arsenijevic
Neda Slobodan Arsenijevic
MGMiona Glisic
Miona Glisic
Background/Objectives: The World Health Organization (WHO) declared a global pandemic of COVID-19 caused by SARS-CoV-2 in March 2020. May 2023 was the month that ended the global pandemic. Pregnant females with COVID-19 are less likely to be symptomatic than non-pregnant patients, with nearly three-quarters being without symptoms. According to previous studies, even if somebody develops symptoms, they are usually mild, most commonly coughing (41%), fever (40%), and dyspnea (21%). Our study aims to search the literature systematically, especially case series and case reports published in Europe, and to summarize results about the kind of COVID-19 therapy in pregnant women and about outcomes in mothers and newborns. Methods: Our systematic review was registered at the International Prospective Register of Systematic Reviews (PROSPERO) with CRD42024566838. We searched PubMed/MEDLINE, Google Scholar, Web of Science, Scopus, and Serbian Citation Index (SCIndeks). In this study, case reports or case series with open, complete text that included full clinical records of the individuals identified with infection in pregnancy, thought to be caused by COVID-19, were used. Case series or case reports were eliminated if they (1) did not contain a full clinical report for every patient, or (2) included an individual who suffered from another viral infection other than COVID-19, so the clinical course and the outcome could not be precisely defined. We evaluated reporting bias and attrition bias. Results: Our study included 32 published studies (eight case series and 24 case reports) that included 56 individual cases. The oldest patient was 50 years old, and the youngest was 19 years old. The most common symptom initially was dry cough (n = 23; 41%), followed by fever (n = 21; 37%) and dyspnea (n = 10; 17%). In three patients, a lower level of thrombocytes was reported, with the lowest level of 86 × 109. The most frequently used drugs in pregnant women with COVID-19 infection were azithromycin, lopinavir/ritonavir, hydroxychloroquine, as well as corticosteroids. Twenty-two patients were on mechanical ventilation. After all this reported therapy, ten women died, as well as seven newborns. Conclusions: From our results, we can conclude that mechanical ventilation correlates with cesarean section performed more frequently, as well as with a higher mortality rate of neonates. There are no significant data related to transplacental transmission of the virus. Generally, mortality in our group of patients (mothers) was 17%, which is similar to the general population death from COVID-19 infection.